Download slidesets from our satellite symposium at SABCS 2018 where expert faculty shared their perspectives on the evolving treatment paradigm in HR+/HER2- MBC, including the subtleties of optimal clinical application of CDK4/6 inhibitor therapy, the latest clinical data on PI3K pathway blockade, and how new strategies may affect management of these patients in the near future.
Download this slideset to review the latest clinical data informing optimal use of CDK4/6 inhibitors in the treatment of HR+/HER2- metastatic breast cancer.
Download this slideset to review the latest clinical data on the evolving role of mTOR and PIK3 inhibitors in the treatment of HR+/HER2- metastatic breast cancer.
Download this slideset to explore future directions in the treatment of HR+/HER2- metastatic breast cancer, including what to do after progression on a CDK4/6 inhibitor and a role for HDAC inhibition.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.